Article Figures & Data
Additional Files
Data Supplement
- Supplemental Data -
Supplementary Table 1 - Validation of all cell lines (MCF-7:WS8, T47D:A18, MCF-7:PF, BT-474, ZR-75-1, MCF-7:5C, MCF-7:2A, and MCF-7:RAL).
Supplementary Figure 1 - Cell viability and proliferation assays in multiple human BC cell lines with test compounds over various time frames.
Supplementary Figure 2 - Cell viability and proliferation assays in multiple human BC cell lines with test compounds in combination with 4OHT and endoxifen.
Supplementary Figure 3 - MD structural analysis.
Supplementary Figure 4 - Human UPR RT2 PCR profiler PCR arrays, proliferation assays, and annexin V staining, in MCF-7:5C cells with 3-day, 7-day, 8-day, and 14-day BPTPE treatments.
Supplementary Figure 5 - Representation of statistically-significant UPR genes that are under-or-over expressed in MCF-7:5C cells treated with test compounds at specific time points.
Supplementary Figure 6 - Detection of UPR in live MCF-7:5C cells using ThT fluorescent dye after 48-hour treatments as measured by the ZEISS Celldiscoverer 7 microscope.
Supplementary Figure 7 - Flow cytometry in MCF-7:5C cells with E2 and E4 plus a PERK inhibitor or an IRE1α inhibitor after 72-hour-treatments.
Supplementary Figure 8 - Flow cytometry in MCF-7:2A cells after 9-and-13-day treatments, and in MCF-7:5C cells after 72-hour treatments.
Supplementary Figure 9 - Flow cytometry in MCF-7:RAL cells after 14-day, 17-day, and 21-day treatments.
Supplementary Figure 10 - Analysis of local fluctuations in the binding site of BMI-135 together with the binding alignment and specific interactions of the ligands in the binding pocket of ERα.
Supplementary Figure 11 - Time-line representations of the monitored interactions and contacts (H-bonds, hydrophobic, ionic, and water bridges) throughout the simulation
- Supplemental Data -
Supplementary Table 1 and Figures 1 - 11
- Supplemental Data -